Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Squalamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.97 |
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.53 |
| ▸ | SLC10A1 | Q14973 | 3/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.51 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Squalamine SCHEMBL14441307 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL17359656 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL16072074 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL13294189 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL12836 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL18838926 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL22356672 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL21248627 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL20850040 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL13014098 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203106-A1 | Method for Producing 5Alpha-Pregnane Derivative | KURARAY CO., LTD. (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070197490-A1 | Method for producing 5alpha-pregnane derivative | KURARAY CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197490-A1 | Method for producing 5alpha-pregnane derivative | KURARAY CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070149494-A1 | Method for producing 5alpha-pregnane derivative | KURARAY CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1767540-A1 | METHOD FOR PRODUCING 5 ALPHA-PREGNANE DERIVATIVE | Kuraray Co., Ltd. (JP) | 2007-03-28 | — | — | EP | disclosed |
| EP-1743902-A1 | METHOD FOR PRODUCING 5ALPHA-PREGNANE DERIVATIVE | Kuraray Co., Ltd. (JP) | 2007-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197490-A1 | Method for producing 5alpha-pregnane derivative | CYP21A2, CYP11B2, SRD5A2 | PTPN1 4438/4885NR1H4 172/4885SLC10A1 132/4885 |
| US-20070203106-A1 | Method for Producing 5Alpha-Pregnane Derivative | SRD5A2, SRD5A1, CYP17A1 | PTPN1 4391/4885NR1H4 217/4885SLC10A1 543/4885 |
| US-20070149494-A1 | Method for producing 5alpha-pregnane derivative | CYP21A2, CYP11B2, NR5A1 | PTPN1 4424/4885NR1H4 134/4885SLC10A1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.